Diabetes mellitus abrogates the cardioprotection of sufentanil against ischaemia/reperfusion injury by altering glycogen synthase kinase-3β

Acta Anaesthesiologica Scandinavica

Volumn 57, Issue 2, 2013, Pages 236-242

  Chen, Q L ^a   Gu, Er Wei ^a   Zhang, L ^a   Cao, Y Y ^a   Zhu, Y ^a   Fang, W P ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; SUFENTANIL; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART INJURY; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; REVIEW; STREPTOZOCIN DIABETES;

ANESTHETICS, INTRAVENOUS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HEART RATE; INDOLES; MALE; MALEIMIDES; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SUFENTANIL; TROPONIN I;

EID: 84872109297     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2012.02748.x     Document Type: Review

References (32)

1. Murray CJ, Lopez AD,. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-1504.
2. Murry CE, Jennings JB, Reimer KA,. Preconditioning with ischemia: a delay of lethal injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
3. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA,. Inhibition of myocardial injury by ischemic post-conditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-588.
4. Gitt AK, Schiele R, Wienbergen H, Zeymer U, Schneider S, Gottwik MG Senges J,. Intensive treatment of coronary artery disease in diabetic patents in clinical practice: results of the MTTRA study. Acta Diabetol 2003; 40: S343-347.
5. Annapurna A, Challa SR, Prakash GJ, Viswanath RK,. Therapeutic potential of sulindac against ischemia-reperfusion induced myocardial infarction in diabetic and nondiabetic rats. Exp Clin Cardiol 2008; 13: 66-70.
6. Gross ER, Hsu AK, Gross GJ,. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3β. Diabetes 2007; 56: 127-136.
7. Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K,. Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 2009; 58: 2863-2872.
8. Yadav HN, Singh M, Sharma PL,. Involvement of GSK-3β in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart. Mol Cell Biochem 2010; 343: 75-81.
9. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC,. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000; 278: H1218-1224.
10. Elder-Finkelman H, Krebs EG,. Increased glycogen synthase kinase-3 activity in diabetes- and obesity prone-C57BL/6J mice. Diabetes 1999; 48: 1662-1666.
11. Gross ER, Hsu AK, Gross GJ,. Opioid-induced cardioprotection occurs via glycogensynthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004; 94: 960-966.
12. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ,. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113: 1535-1549.
13. Obame FN, Plin-Mercier C, Assaly R, Zini R, Dubois-Rande JL, Berdeaux A, Morin D,. Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3β, SB216763 [3-(2,4-dichlorophenyl)-4 (1-methyl-1H-indol -3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore. J Pharmacol Exp Ther 2008; 326: 252-258.
14. Wu Y, Gu EW, Zhu Y, Zhang L, Liu XQ, Fang WP,. Sufentanil limits the myocardial infarct size by preservation of the phosphorylated connexin 43. Int Immunopharmacol 2012; 13: 341-346.
15. Lemoine S, Zhu L, Massetti M, Gérard JL, Hanouz JL,. Continuous administration of remifentanil and sufentanil induces cardioprotection in human myocardium, in vitro. Acta Anaesthesiol Scand 2011; 55: 758-764.
16. Ozansoy G, Akin FB,. Effects of gemfibrozil treatment on vascular reactivity of streptozotocin- diabetic rat aorta. J Pharm Pharmacol 2004; 56: 241-246.
17. Zhang Y, Chen ZW, Girwin M, Wong TM,. Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats. Acta Pharmacol Sin 2005; 265: 46-50.
18. Liu XS, Xue QS, Zeng QW, Li Q, Liu J, Feng XM, Yu BW,. Sevoflurane impairs memory consolidation in rats, possibly through inhibiting phosphorylation of glycogen synthase kinase-3β in the hippocampus. Neurobiol Learn Mem 2010; 94: 461-467.
19. Bhavsar R, Sloth E, Folkersen L, Greisen JR, Jakobsen CJ,. Sufentanil preserves hemodynamics and left ventricular function in patients with ischemic heart disease. Acta Anaesthesiol Scand 2011; 55: 1002-1009.
20. Chen Z, Li T, Zhang B,. Morphine post-conditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res 2008; 145: 287-294.
21. Wong GT, Li R, Jiang LL, Irwin MG,. Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand 2010; 54: 510-518.
22. Tosaki A, Engelman DT, Engelman RM, Das DK,. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 1996; 31: 526-536.
23. Ferdinandy P, Schulz R, Baxter GF,. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and post- conditioning. Pharmacol Rev 2007; 59: 418-458.
24. Halestrap AP, Clarke SJ, Javadov SA,. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res 2004; 61: 372-385.
25. Pacher P, Hajno'czky G,. Propagation of the apoptotic signal by mitochondrial waves. EMBO J 2001; 20: 4107-4121.
26. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M,. Inhibition of GSK3β by post-conditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 2008; 117: 2761-2768.
27. Miura T, Miki T,. GSK-3beta, a therapeutic target for cardiomyocyte protection. Circ J 2009; 73: 1184-1192.
28. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ,. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104: 1240-1252.
29. Miura T, Nishihara M, Miki T,. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury. J Pharmacol Sci 2009; 109: 162-167.
30. Desrois M, Sidell RJ, Gauguier D, King LM, Radda GK, Clarke K,. Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res 2004; 61: 288-296.
31. Paulson DJ,. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 1997; 34: 104-112.
32. Ravingerova T, Stetka R, Volkovova K, Pancza D, Dzurba A, Ziegelhoffer A, Styk J,. Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 2000; 210: 143-151.